Efficacy and Safety of Rociletinib Versus Chemotherapy in Patients With EGFR-Mutated NSCLC: The Results of TIGER-3, a Phase 3 Randomized Study

CHIH-HSIN YANGReckamp K.L.Kim Y.-C.Novello S.Smit E.F.Lee J.-S.Su W.-C.Akerley W.L.Blakely C.M.Groen H.J.M.Bazhenova L.Carcereny Costa E.Chiari R.Hsia T.-C.Golsorkhi T.Despain D.Shih D.Popat S.Wakelee H.2022-08-102022-08-1020212666-3643https://www.scopus.com/inward/record.uri?eid=2-s2.0-85102035727&doi=10.1016%2fj.jtocrr.2020.100114&partnerID=40&md5=5781ed8741870310590f9aadccd8fc46https://scholars.lib.ntu.edu.tw/handle/123456789/616506Efficacy and Safety of Rociletinib Versus Chemotherapy in Patients With EGFR-Mutated NSCLC: The Results of TIGER-3, a Phase 3 Randomized Studyjournal article10.1016/j.jtocrr.2020.1001142-s2.0-85102035727